Company profile
Nkarta, Inc.
NASDAQ:NKTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Belacabnagene Franleucel | phase1_2 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06557265 | phase1_2 | recruiting | 2024-06-13 | 2027-04-01 | Nkarta, Inc. | A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) |
| NCT06733935 | phase1_2 | recruiting | 2024-11-04 | 2028-10-01 | Nkarta, Inc. | A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) |
| NCT05020678 | phase1 | active_not_recruiting | 2021-08-20 | 2025-03-31 | Nkarta, Inc. | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers |
| NCT04623944 | phase1 | active_not_recruiting | 2020-09-21 | 2024-10-02 | Nkarta, Inc. | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS |
FDA applications (0)
No records yet.